Crossmark Global Holdings Inc. Cuts Position in West Pharmaceutical Services, Inc. $WST

Crossmark Global Holdings Inc. decreased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 21.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,447 shares of the medical instruments supplier’s stock after selling 2,555 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in West Pharmaceutical Services were worth $2,478,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. CYBER HORNET ETFs LLC purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 95 shares in the last quarter. SJS Investment Consulting Inc. grew its stake in West Pharmaceutical Services by 1,842.9% in the 3rd quarter. SJS Investment Consulting Inc. now owns 136 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 129 shares during the period. MUFG Securities EMEA plc acquired a new stake in West Pharmaceutical Services in the 2nd quarter valued at $47,000. Finally, Pilgrim Partners Asia Pte Ltd purchased a new stake in West Pharmaceutical Services in the 3rd quarter worth $47,000. 93.90% of the stock is owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Up 0.6%

Shares of WST opened at $245.92 on Friday. West Pharmaceutical Services, Inc. has a 52-week low of $187.43 and a 52-week high of $322.34. The stock has a market cap of $17.71 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 2.61 and a beta of 1.17. The firm’s fifty day moving average is $253.72 and its two-hundred day moving average is $262.14. The company has a quick ratio of 2.34, a current ratio of 3.02 and a debt-to-equity ratio of 0.06.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.21. The business had revenue of $805.00 million during the quarter, compared to analysts’ expectations of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.82 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. Research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be issued a $0.22 dividend. The ex-dividend date is Wednesday, April 29th. This represents a $0.88 dividend on an annualized basis and a yield of 0.4%. West Pharmaceutical Services’s dividend payout ratio is presently 12.96%.

West Pharmaceutical Services announced that its board has initiated a share repurchase plan on Tuesday, February 17th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 5.6% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

West Pharmaceutical Services News Roundup

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: Zacks Research raised several near?term and multi?year EPS estimates for WST (notable changes: FY2026 to $7.85 from $7.52, FY2027 to $8.79 from $8.51, and FY2028 to $10.29) and upgraded multiple quarter forecasts (Q1–Q4 2026 and Q1/Q4 2027). The firm keeps a “Strong?Buy” rating — a coordinated set of upgrades that tends to support investor conviction and share demand. MarketBeat: West Pharmaceutical Services
• Neutral Sentiment: These revisions largely align with West’s own FY2026 guidance range (7.85–8.20 EPS), so part of the move may reflect confirmation of management direction rather than a surprise beat. Analysts’ models can change and represent expectations, not guarantees.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on WST shares. UBS Group restated a “buy” rating and set a $340.00 price objective on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research note on Friday, February 13th. Zacks Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $295.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, February 10th. Finally, Evercore lowered their price objective on West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a report on Tuesday, February 3rd. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, West Pharmaceutical Services presently has a consensus rating of “Buy” and a consensus price target of $314.56.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.